Roselli M, Guadagni F, Buonomo O, Belardi A, Ferroni P, Diodati A, Anselmi D, Cipriani C, Casciani C U, Greiner J, Schlom J
Department of Surgery, University of Rome Tor Vergata, Italy.
Anticancer Res. 1996 Jul-Aug;16(4B):2187-92.
Monoclonal antibodies (MAbs) that are reactive with tumor associated antigens (TAAs) have led to many of the recent advances made in tumor immunology. At the present time, many of these MAbs have already been used in various aspects of patient management and in better understanding the biology of carcinoma cell populations. Because of their diversity, specificity and biological activity, these MAbs are potentially ideal agents for a variety of applications in malignant disorders such as, clinical diagnosis using serum assays, immunocytopathological analyses of effusions or fine-needle aspiration specimens, immunoscintigraphy, radioimmunoguided surgery and, with additional development, site directed immunotherapy. Nevertheless, their clinical application shows advantages and limitations. Optimization of their clinical use is actually under evaluation in several Institutions, including our Department. Many innovations have been developed over the last decade which may enhance their clinical efficacy. In this view, an optimal tumor targeting for diagnostic or therapeutic applications may require a better choice of radiotracer, generation of new molecules and the characterization of TAAs at the target level.
与肿瘤相关抗原（TAA）反应的单克隆抗体（MAb）引领了肿瘤免疫学领域近期的诸多进展。目前，许多此类单克隆抗体已被应用于患者管理的各个方面，并有助于更好地了解癌细胞群体的生物学特性。由于其多样性、特异性和生物活性，这些单克隆抗体在恶性疾病的多种应用中具有潜在的理想特性，如使用血清检测进行临床诊断、对积液或细针穿刺标本进行免疫细胞病理学分析、免疫闪烁显像、放射免疫导向手术，以及随着进一步发展的靶向免疫治疗。然而，它们的临床应用既有优势也有局限性。包括我们科室在内的多个机构目前正在评估如何优化其临床应用。在过去十年中已开发出许多创新方法，可能会提高它们的临床疗效。从这个角度来看，针对诊断或治疗应用的最佳肿瘤靶向可能需要更好地选择放射性示踪剂、生成新分子以及在靶点水平对肿瘤相关抗原进行表征。
